Categories Analysis, U.S. Markets News

Tilray earnings preview: Investors need more than just production expansion

Though the marijuana industry has been seeing overall tremendous growth, one prominent name has been pulling it down – Tilray (NASDAQ: TLRY). Even as other pot stocks gained considerably since the beginning of this year, Tilray has plunged over 36%, much to the annoyance of investors.

The Canadian marijuana firm is slated to report first-quarter earnings results on May 14, Tuesday after the market closes. Analysts are expecting another quarterly loss, this time of 25 cents per share, as the company continues to invest heavily on production expansion. Revenues are estimated to be $21.6 million, compared to $15.5 million it reported in the prior sequential quarter.

Reports of production ramps have already been priced into the stock, which is still struggling to reverse its downward trajectory. Despite the ramps, Tilray continues to underperform when compared to peers such as Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE: ACB).

Cannabis Stocks- Performance Comparison

Investors are also concerned over Tilray’s inability to turn profitable, despite some of its peers starting to make money. During the last reported quarter, the company had reported a net loss of $31 million, or $0.33 per share, wider than the previous year’s loss of $3 million, or $0.04 per share.

The big beverage partnership

The partnership with Budweiser-parent Anheuser Busch Inbev (NYSE: BUD) to produce cannabis-based beverages had been touted as the biggest USP of Tilray going forward. However, Wall Street has started losing interest in this following reports that Anheuser’s lack of materialistic commitment towards this project.

Meanwhile, New Age Beverages Corporation (NASDAQ: NBEV) has made considerable headway in this regard, by inking a deal to develop and distribute Marley branded cannabis-infused beverages.

READ: THE QUESTION EVERY POT INVESTOR ASKS HIMSELF – AURORA CANNABIS OR HEXO?

Tilray has made other promising partnerships as well, including ones with Novartis (NYSE: NVS) and Authentic Brands Group. But its high time the partnerships start showing up benefits in the balance sheet as well.

Consecutive bearish comments from analysts and estimate revisions have hurt the confidence of investors in the stock, at least for the short-term.

Tilray management has a mammoth job of convincing people to stay invested as it heads to the conference call on Tuesday. The company is likely to focus on its long-term prospects and path to profitability.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

PG Earnings: Procter & Gamble Q3 profit climbs, beats estimates

Consumer goods behemoth The Procter & Gamble Company (NYSE: PG) announced financial results for the third quarter of 2024, reporting a double-digit growth in net profit. Sales rose modestly. Core

AXP Earnings: All you need to know about American Express’ Q1 2024 earnings results

American Express Company (NYSE: AXP) reported its first quarter 2024 earnings results today. Consolidated total revenues, net of interest expense, increased 11% year-over-year to $15.8 billion, driven mainly by higher

Netflix (NFLX) Q1 2024 profit tops expectations; adds 9.3Mln subscribers

Streaming giant Netflix, Inc. (NASDAQ: NFLX) Thursday reported a sharp increase in net profit for the first quarter of 2024. Revenues were up 15% year-over-year. Both numbers exceeded Wall Street's

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top